Literature DB >> 11166464

Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion.

S M Devine1, A M Bartholomew, N Mahmud, M Nelson, S Patil, W Hardy, C Sturgeon, T Hewett, T Chung, W Stock, D Sher, S Weissman, K Ferrer, J Mosca, R Deans, A Moseley, R Hoffman.   

Abstract

OBJECTIVE: The human bone marrow contains mesenchymal stem cells capable of differentiating along multiple mesenchymal cell lineages. Using a non-human primate model, we sought to determine whether the systemic infusion of baboon-derived mesenchymal stem cells was associated with toxicity and whether these cells were capable of homing to and persisting within the bone marrow.
MATERIALS AND METHODS: Five baboons (Papio anubis) were administered lethal irradiation followed by intravenous autologous hematopoietic progenitor cells combined with either autologous (n = 3) or allogeneic (n = 2) mesenchymal stem cells that had been expanded in culture. In four of these baboons, the mesenchymal stem cells were genetically modified with a retroviral vector encoding either the enhanced green fluorescent protein gene (n = 3) or the human placental alkaline phosphatase gene (n = 1) for tracking purposes. A sixth animal received only intravenous gene marked autologous mesenchymal stem cells but no hematopoietic stem cells or conditioning irradiation.
RESULTS: Following culture, baboon mesenchymal stem cells appeared morphologically as a homogeneous population of spindle-shaped cells that were identified by the monoclonal antibodies SH-3 and SH-4. These cells did not express the hematopoietic markers CD34 or CD45. Baboon mesenchymal stem cells isolated from primary culture were capable of differentiating along both adipogenic and osteogenic lineages. There was no acute or chronic toxicity associated with the intravenous infusion of mesenchymal stem cells. In all five recipients of gene marked mesenchymal stem cells, transgene was detected in post-transplant bone marrow biopsies. In two animals receiving autologous mesenchymal stem cells, including the one non-conditioned recipient, transgene could be detected over 1 year following infusion. In one recipient of allogeneic gene marked mesenchymal stem cells, transgene was detected in the bone marrow at 76 days following infusion.
CONCLUSION: These data demonstrate that baboon mesenchymal stem cells: 1) are not associated with significant toxicity when administered intravenously, 2) are capable of homing to the bone marrow following intravenous infusion, and 3) have the capacity to establish residence within the bone marrow for an extended duration following systemic administration.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11166464     DOI: 10.1016/s0301-472x(00)00635-4

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  94 in total

1.  Allogeneic mesenchymal stem cells do not protect NZBxNZW F1 mice from developing lupus disease.

Authors:  M Youd; C Blickarz; L Woodworth; T Touzjian; A Edling; J Tedstone; M Ruzek; R Tubo; J Kaplan; T Lodie
Journal:  Clin Exp Immunol       Date:  2010-04-29       Impact factor: 4.330

Review 2.  Tomorrow's skeleton staff: mesenchymal stem cells and the repair of bone and cartilage.

Authors:  W R Otto; J Rao
Journal:  Cell Prolif       Date:  2004-02       Impact factor: 6.831

Review 3.  Mesenchymal stromal cells for cell therapy: besides supporting hematopoiesis.

Authors:  Lei Hao; Huiqin Sun; Jin Wang; Tao Wang; Mingke Wang; Zhongmin Zou
Journal:  Int J Hematol       Date:  2011-12-20       Impact factor: 2.490

Review 4.  Mesenchymal stem cells: Mechanisms of immunomodulation and homing.

Authors:  Hiroshi Yagi; Alejandro Soto-Gutierrez; Biju Parekkadan; Yuko Kitagawa; Ronald G Tompkins; Naoya Kobayashi; Martin L Yarmush
Journal:  Cell Transplant       Date:  2010-06-03       Impact factor: 4.064

5.  Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-gamma.

Authors:  Jennifer L Chan; Katherine C Tang; Anoop P Patel; Larissa M Bonilla; Nicola Pierobon; Nicholas M Ponzio; Pranela Rameshwar
Journal:  Blood       Date:  2006-02-21       Impact factor: 22.113

6.  Effect of mesenchymal stem cell transplantation on the engraftment of human hematopoietic stem cells and leukemic cells in mice model.

Authors:  Seung-Tae Lee; Hoyoung Maeng; Yong-Joon Chwae; Duk Jae Oh; Yong-Man Kim; Woo Ick Yang
Journal:  Int J Hematol       Date:  2008-02-22       Impact factor: 2.490

Review 7.  Murine bone marrow-derived mesenchymal stem cells as vehicles for interleukin-12 gene delivery into Ewing sarcoma tumors.

Authors:  Xiaoping Duan; Hui Guan; Ying Cao; Eugenie S Kleinerman
Journal:  Cancer       Date:  2009-01-01       Impact factor: 6.860

8.  Mesenchymal stem cells: from biology to clinical use.

Authors:  Mauro Krampera; Massimo Franchini; Giovanni Pizzolo; Giuseppe Aprili
Journal:  Blood Transfus       Date:  2007-07       Impact factor: 3.443

Review 9.  [Regenerative potential of human adult precursor cells: cell therapy--an option for treating cartilage defects?].

Authors:  T Dehne; M Tschirschmann; R Lauster; M Sittinger
Journal:  Z Rheumatol       Date:  2009-05       Impact factor: 1.372

10.  Umbilical cord blood transplantation.

Authors:  Hong Hoe Koo; Hyo Seop Ahn
Journal:  Korean J Pediatr       Date:  2012-07-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.